左西孟旦注射液治疗慢性阻塞性肺疾病伴心功能不全的临床研究

发布时间：2018-05-19 19:02

  本文选题：左西孟旦 + 硫酸特布他林　； 参考：《中国临床药理学杂志》2017年16期

【摘要】：目的观察左西孟旦联合硫酸特布他林治疗慢性阻塞性肺疾病伴心功能不全的临床疗效及安全性。方法将88例慢性阻塞性肺疾病伴心功能不全患者随机分为对照组44例与试验组44例,2组均给予常规治疗及对症治疗。对照组给予吸入用布地奈德混悬液1 mg+硫酸特布他林雾化液5 mg于射流雾化器内,氧气驱动雾化吸入,每日2次,呋塞米20~40 mg,静脉推注2~3 h。试验组在对照组的基础上给予左西孟旦0.1μg·kg~(-1)·min~(-1)静脉输注,持续给药24 h。2组患者均持续用药7 d。比较2组患者的临床疗效、肌钙蛋白T、心肌酶谱、心肺功能及药物不良反应发生情况。结果治疗后,试验组总有效率为88.64%(39/44例),对照组为70.45%(31/44例,P0.05)。治疗后,对照组和试验组肌钙蛋白T分别为(0.48±0.06),(0.18±0.03)μg·L~(-1);肌酸激酶分别为(189.29±21.30),(130.27±16.11)U·L~(-1);肌酸激酶同工酶分别为(11.34±1.71),(8.87±1.09)U·L~(-1);乳酸脱氢酶分别为(159.29±17.11),(138.70±14.51)U·L~(-1);左心室舒张末期内径分别为(50.29±5.79),(47.01±5.01)mm;第1秒用力呼气量分别为(1.35±0.19),(1.70±0.23)L;第1秒用力呼气量/用力肺活量(FEV1/FVC)分别为(60.93±7.09)%,(76.94±8.58)%;左心室射血分数分别为(42.39±4.58)%,(51.29±5.71)%;6 min内的最大步行距离分别为(260.39±29.21),(324.29±35.16)m,差异均有统计学意义(均P0.05)。试验组的药物不良反应有心悸、头痛、眩晕,药物不良反应发生率为6.82%(3/44例);对照组的药物不良反应有体位性低血压、低钠血症、心律失常、口渴,药物不良反应发生率为11.36%(5/44例),差异无统计学意义(P0.05)。结论左西孟旦联合硫酸特布他林治疗慢性阻塞性肺疾病伴心功能不全的临床疗效较高,安全性高。
[Abstract]:Objective to observe the efficacy and safety of levosimendan combined with terbutaline sulfate in the treatment of chronic obstructive pulmonary disease with cardiac insufficiency. Methods 88 patients with chronic obstructive pulmonary disease complicated with cardiac insufficiency were randomly divided into control group (n = 44) and experimental group (n = 44). The control group was treated with budesonide suspension (1 mg) and terbutaline sulfate (5 mg) in the jet atomizer. Oxygen driven atomization was administered twice a day, furosemide 2040 mg, intravenous injection for 23 h. On the basis of the control group, the patients in the trial group were given levsimendan 0.1 渭 g / kg, 1 渭 g / min / min, iv infusion, and the patients in the 24 h / 2 group were treated continuously for 7 days. The clinical efficacy, cardiac troponin T, myocardial enzyme spectrum, cardiopulmonary function and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rate of the trial group was 88.64 / 39 / 44 cases, and that of the control group was 70.45% / 44 cases (P 0.05). After treatment, 瀵圭収缁勫拰璇曢獙缁勮倢閽欒泲鐧絋鍒嗗埆涓，

本文编号：1911273